Sarepta Therapeutics (SRPT) closed at $17.73 on Oct 19, 2026, up 3.7% on the day. The stock is down 11.8% over the past month, up 9.4% over three months, down 17.6% year to date and down 24.0% over the past year. It trades 28.2% below its 52-week high of $24.68 and 20.7% above its 52-week low of $14.69. The close sits below its 50-day moving average ($19.20) and below its 200-day moving average ($18.89).
NextPick tracks SRPT in its Biotech basket alongside VRTX, MRNA, REGN, BIIB and ALNY. As of Oct 19, 2026, the basket's money-flow score is -20 (weak outflow), and the basket is down 1.1% over five sessions. Over the past month SRPT ranks 13th of 17 basket members by price change.
No — the Oct 19, 2026 close of $17.73 is 6.1% below the 200-day average of $18.89.
SRPT closed 28.2% below its 52-week high of $24.68.
NextPick groups SRPT with VRTX, MRNA, REGN, BIIB and ALNY in its Biotech basket.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
